Quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.
We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In order to make this vision a reality, we brought together the most experienced management team, renowned scientists, industry leading investors and expert advisors, to form a collaborative ecosystem, united through the common goal of advancing the science of precision health.
The Simoa Accelerator Lab is an innovation center for biomarker research, custom assay development and clinical sample testing. With nearly 300 completed projects and over 25,000 samples tested for researchers from over a dozen countries in Europe, the Middle East and Africa, the state-of-the-art facility provides access to the revolutionary Simoa technology. Researchers, academics and private investigators can work side-by-side with Quanterix scientists to test specimens with existing Simoa assays, or prototype, develop and optimize new assays.
Quanterix Corporation has not received any reviews.
Quanterix Corporation has not received any endorsements.